Schröder Fritz H
Department of Urology, Erasmus University MC, Academic Hospital Rotterdam, Dr. Molewaterplein 40, 3015 GD Rotterdam, The Netherlands.
Urol Clin North Am. 2003 May;30(2):239-51, viii. doi: 10.1016/s0094-0143(02)00180-5.
This article provides a review of present evidence that suggests that screening achieves a reduction in prostate cancer mortality. Aspects of quality of life and cost effectiveness are reviewed, as well as present test performance. The questions addressed in this article include the following: Is screening in its present form acceptable as a public health instrument? What changes are needed to improve the screening procedure? What are the research priorities in this field, assuming that the present evidence of prostate cancer mortality reduction is eventually confirmed by ongoing randomized controlled trials?
本文综述了目前表明筛查可降低前列腺癌死亡率的证据。对生活质量、成本效益等方面以及当前的检测性能进行了综述。本文探讨的问题包括：目前形式的筛查作为一种公共卫生手段是否可接受？需要哪些改变来改进筛查程序？假设目前前列腺癌死亡率降低的证据最终被正在进行的随机对照试验所证实，该领域的研究重点是什么？
